August 1st, 2011, Shenzhen, China and San Diego, CA – BGI, the world's largest genomics organization, and GT Life Sciences, Inc., a privately held biotechnology company that utilizes a proven metabolic modeling and experimental platform to drive the discovery and design of new products and processes for the life sciences field, announced today that their collaborative study on the genomic sequence of the Chinese hamster ovary (CHO) K1 cell line was published online in Nature Biotechnology. The CHO-K1 genome is the first published cell line genome decoded by de novo sequencing and assembly. The study yields a better understanding of the genetics of CHO cells and will accelerate the discovery and development of new recombinant protein therapies.
Chinese hamster ovary (CHO) cell lines are mammalian cells derived from the ovary of the Chinese hamster and are the preferred and most commonly used mammalian hosts today in biological and medical research. These cell lines play an important role in bioprocessing research and the development of therapeutic biopharmaceuticals. Currently the worldwide market for recombinant therapeutic proteins totals more than 99 billion USD in annual revenue from a broad range of products, including monoclonal antibodies, growth factors, hormones, and blood factors.
"Recognizing the importance of CHO cell lines, we and our partners jointly initiated a study of the genome sequence of CHO-K1 cells," said co-leading author of the study Xun Xu, Vice President of Research and Development at BGI and CEO BGI Americas. "The genome sequence and comprehensive annotation of the CHO-K1 cell line provides a useful and powerful tool for scientists in biomedical areas to optimize the production process and improve the yield of therapeutic proteins," he added.
GT Life Sciences' established business platform for metabolic modeling and engineering of mammalian cells has already proven effective in optimizing CHO cell media and developing novel selectable markers. With the advanced genome sequencing capability of BGI, the CHO-K1 ancestral cell line was sequenced by de novo sequencing and then assembled by BGI's Short Oligonucleotide Analysis Package, SOAPdenovo, resulting in the assembly of 2.45 Gb of the genomic sequence. This information was combined with transcriptome sequence data and led to the generation of 24,383 predicted genes.
"After working with cell culture for over 20 years, this is a dream come true," said Bernhard Palsson, Ph.D., co-founder of GT Life Sciences. "We can now hope to develop metabolic and cell line engineering procedures that approach those currently available for E. coli and yeast. This development signifies the start of genome-scale science for CHO."
"The CHO cell line genome revealed the secret of its protein synthesis, modification and viral resistance, which are very unique among other cell lines and make it the optimal protein production tool." said Xu. Because of the fact that differential glycosylation can substantially affect functional activity and immune responses, researchers carried out a genome-scale assessment of CHO-K1 genes involved in protein glycosylation pathways. They identified homologs to 99% of the human glycosylation-associated genes in the CHO-K1 genome, with 53% of them expressed. The high coverage of homologs provides a unique opportunity for glycoform manipulation in CHO cells. According to the report, the genome of CHO-K1 also provided insight into viral susceptibility genes and found that key genes associated with viral entry are not expressed in CHO-K1.
"Coupling the CHO sequence with a complete genome-scale model of CHO metabolism will prove highly productive in our ability to deliver next-generation process technologies for biopharmaceutical production in CHO and other mammalian cell lines," added Iman Famili, Ph.D., Sr. Director, Research and Development at GT Life Sciences.
"The CHO-K1 genome provides the foundation for studies of other CHO cell lines and is a major step forward in the application of genomics in the production of biopharmaceuticals," stated Dr. Jun Wang, Executive Director of BGI. "We expect that cell line engineering will be facilitated by genomics applications and the biopharmaceutical industry as well human healthcare will gain great benefits."
As previously reported, BGI and GT Life Sciences, Inc. jointly announced the complete sequencing and the publicly available access to the CHO genomic sequence in January of this year (http://www.bgisequence.com/us/newsandevents/news/bgi-and-gt-life-sciences/), providing an early valuable resource for biomedical researchers.
About GT Life Sciences, Inc.
GT Life Sciences (GT) is a privately held biotechnology company that utilizes a proven metabolic modeling and experimental platform to drive the discovery and design of new products and processes for the life sciences field. GT is a world leader in mammalian cell metabolism, biochemical reactions, enzymatic transformations, networks and systems that control processes in cells. GT's platform is being applied to accelerate biological research, discovery and product development for both GT and its partners in a number of commercial opportunity areas in which cellular metabolism plays an important role. For more information, visit www.gtlifesciences.com.
BGI (formerly known as the Beijing Genomics Institute) was founded in Beijing, China on September 9th, 1999 with the mission of being a premier scientific partner to the global research community. The company's goal is to make leading-edge genomic science highly accessible through its investment in infrastructure that leverages the best available technology, economies of scale, and expert bioinformatics resources. BGI and its affiliates, BGI Americas and BGI Europe, have established partnerships and collaborations with leading academic and government research institutions as well as global biotechnology and pharmaceutical companies, in supporting a variety of disease, agricultural, environmental, and related applications. BGI has established a proven track record of excellence, delivering results with high efficiency and accuracy for innovative, high-profile research that has been published to date in more than 50 top-tier academic journals. These accomplishments include sequencing one percent of the human genome for the International Human Genome Project, contributing 10 percent to the International Human HapMap Project, carrying out research to combat SARS and German deadly E. coli, playing a key role in the Sino-British Chicken Genome Project, and completing the sequence of the rice genome, the silkworm genome, the first Asian diploid genome, the potato genome, and, most recently, 1000 genomes and human Gut metagenome. For more information about BGI please visit www.genomics.cn or www.bgiamericas.com
Chief Executive Officer, BGI Americas and
Vice President, Research and Development, BGI
Iman Famili, Ph.D.
Director, Research and Development
GT Life Sciences, Inc.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.